您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > (S)-Lisofylline
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
(S)-Lisofylline
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
(S)-Lisofylline图片
CAS NO:100324-80-9
包装与价格：
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
inactive optical enantiomer of (R)-LSF, an anti-inflammatory agent
Cas No.100324-80-9
别名(+)-Lisofylline,(S)-LSF
化学名3,7-dihydro-1-[5S-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione
Canonical SMILESO=C(N(C)C1=C2N(C)C=N1)N(CCCC[C@@H](O)C)C2=O
分子式C13H20N4O3
分子量280.3
溶解度≤15mg/ml in ethanol;3mg/ml in DMSO;12mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Lisofylline (LSF) is a potent anti-inflammatory agent. LSF is a chiral metabolite of pentoxifylline [1]. Pentoxifylline is exclusively reduced to (S)-LSF in the cytosol when metabolized by isolated human liver cells [2].

In vitro: Lisofylline preserved β-cell insulin secretion and inhibited DNA damage of islets in the presence of IL-1β [3]. Simultaneous application of LSF and cytokines to INS-1 cells restored insulin secretion, mitochondrial membrane potential, MTT metabolism, and cell viability to control levels. LSF increased β-cell MTT metabolism as well as insulin release and glucose responsiveness [4].

In vivo: In rats subjected to hemorrhagic shock and resuscitation, LSF increased the intestinal and hepatic blood flow. Treatment with LSF (15 mg/kg) ameliorated the development of mucosal damage and hyperpermeability. Rats treated with LSF showed lower plasma concentrations of the intracellular hepatic enzyme, aspartate aminotransferase. LSF treatment increased concentrations of adenosine triphosphate in intestinal and hepatic tissue [1]. In NOD mice, lisofylline suppressed IFN-γ production, reduced the onset of insulitis and diabetes, and inhibited diabetes after transfer of splenocytes from Lisofylline-treated donors to NOD.scid recipients [3].

References:
[1] Wattanasirichaigoon S, Menconi M J, Fink M P.  Lisofylline ameliorates intestinal and hepatic injury induced by hemorrhage and resuscitation in rats[J]. Critical care medicine, 2000, 28(5): 1540-1549.
[2] Lillibridge, J. A.,Kalhorn, T.F. and Slattery, J.T. Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metabolism and Disposition 24(11), 1174-1179 (1996).
[3] Yang Z D, Chen M, Wu R, et al.  The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice[J]. Diabetologia, 2002, 45(9): 1307-1314.
[4] Chen M, Yang Z, Wu R, et al.  Lisofylline, a novel antiinflammatory agent, protects pancreatic β-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism[J]. Endocrinology, 2002, 143(6): 2341-2348.